Oxaliplatin versus Irinotecan in advanced colorectal cancer

Authors

DOI:

https://doi.org/10.11606/issn.2176-7262.rmrp.2022.189669

Keywords:

Irinotecan, Oxaliplatin, Metastatic colorectal cancer, Colorectal neoplasms

Abstract

Colorectal cancer is a highly prevalent and lethal neoplasm. The reason for this high number of deaths is the detection of the disease in metastatic stages, which are difficult to cure and require adjuvant or palliative chemotherapy therapy. Currently, the main chemotherapeutic treatment of this neoplasm is based on the drugs Oxaliplatin or Irinotecan, alone or combined with other drugs. The objective of this systematic review is to evaluate whether there is superiority of the chemotherapy regimen with Irinotecan over that with Oxaliplatin. Analysis of randomized clinical trials, phase II or III, was performed in the electronic databases Central and PubMed. Inclusion criteria: randomized clinical trials comparing irinotecan- or oxaliplatin-based regimens as first-line treatments for metastatic colorectal cancer. The primary endpoint analyzed was the superiority between chemotherapies on overall survival. Secondary endpoints included progression-free survival, response rate, and side effects. PROSPERO registration: CRD42019130339. There was no significant difference in the 13 studies on patient survival. On drug side effects, irinotecan-based regimens were associated with a high incidence of neutropenia and severe diarrhea. Those associated with oxaliplatin were associated with a high incidence of sensory neuropathy. There was no statistically significant difference in overall survival, progression-free survival, and response rate when comparing patients receiving oxaliplatin and irinotecan.

Downloads

Download data is not yet available.

Author Biographies

  • Thaís Árabe do Prado, Centro Universitário das Faculdades Associadas de Ensino, São João da Boa Vista, (SP), Brasi

    Acadêmicos de medicina

  • Giovanna Volpe Del Bel, Centro Universitário das Faculdades Associadas de Ensino, São João da Boa Vista, (SP), Brasi

    Acadêmicos de medicina

  • Milena Bongiorno Levignali, Centro Universitário das Faculdades Associadas de Ensino, São João da Boa Vista, (SP), Brasi

    Acadêmicos de medicina

  • Uanderson Resende, Centro Universitário das Faculdades Associadas de Ensino, São João da Boa Vista, (SP), Brasi

    Ph.D; Professor de medicina

References

- Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de câncer no Brasil / Instituto Nacional de Câncer José Alencar Gomes da Silva. – Rio de Janeiro: INCA, 2019

- Moreno CC, Mittal PK, Sullivan PS, Rutherford R, Staley CA, Cardona K, Hawk NN, Dixon WT, Kitajima HD, Kang J, Small WC, Oshinski J, Votaw JR. Colorectal Cancer Initial Diagnosis: Screening Colonoscopy, Diagnostic Colonoscopy, or Emergent Surgery, and Tumor Stage and Size at Initial Presentation. Clin Colorectal Cancer. 2016 Mar;15(1):67-73. doi: 10.1016/j.clcc.2015.07.004. Epub 2015 Jul 29. PMID: 26602596.

- Amri R, Bordeianou LG, Sylla P, Berger DL. Impact of screening colonoscopy on outcomes in colon cancer surgery. JAMA Surg. 2013 Aug;148(8):747-54. doi: 10.1001/jamasurg.2013.8. PMID: 23784448.

- Seymour, M. T., Maughan, T. S., Ledermann, J. A., Topham, C., James, R., Gwyther, S. J., … Stephens, R. J. (2007). Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. The Lancet, 370(9582), 143–152. doi:10.1016/s0140-6736(07)61087-3

- Schmiegel W, Reinacher-Schick A, Arnold D, et al. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Ann Oncol. 2013;24:1580– 7. https://doi.org/10.1093/annonc/mdt028.

- Feliu J, Castañón C, Salud A, et al. Phase II randomised trial of raltitrexedoxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer. Br J Cancer. 2005;93:1230–5. https://doi.org/10.1038/sj.bjc. 6602860.

- Nakayama G, Mitsuma A, Sunagawa Y, et al. Randomized phase II trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as first-line treatment for Japanese patients with metastatic colorectal cancer (CCOG1201 study). Oncologist. 2018;23:919–27. https://doi.org/10.1634/ theoncologist.2017-0640.

- Parikh AR, Lee FC, Yau L, et al. MAVERICC, a randomized, biomarkerstratified, phase II study of mFOLFOX6-Bevacizumab versus FOLFIRIBevacizumab as first-line chemotherapy in metastatic colorectal cancer. Clin Cancer Res. 2019;25:2988–95. https://doi.org/10.1158/1078-0432.CCR-18- 1221.

- Carrato A, Abad A, Massuti B, et al. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: a randomised, phase II trial (PLANET-TTD). Eur J Cancer. 2017;81:191–202. https://doi.org/10.1016/j.ejca.2017.04.024.

- Folprecht G, Gruenberger T, Bechstein W, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/ cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 2014;25:1018–25. https://doi.org/10.1093/annonc/ mdu088.

- Yamazaki K, Nagase M, Tamagawa H, et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 2016;27:1539–46. https://doi.org/10.1093/annonc/mdw206.

- Ocvirk J, Brodowicz T, Wrba F, et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol. 2010;16: 3133–43. https://doi.org/10.3748/wjg.v16.i25.3133

- Rosati G, Cordio S, Bordonaro R, et al. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Ann Oncol. 2010;21:781–6. https:// doi.org/10.1093/annonc/mdp359.

- Bajetta E, Di Bartolomeo M, Buzzoni R, et al. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Br J Cancer. 2007;96:439–44. https://doi.org/10.1038/sj.bjc. 6603493

- Comella P, Massidda B, Filippelli G, et al. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus highdose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a southern Italy cooperative oncology group phase III trial. Ann Oncol. 2005;16:878–86. https://doi.org/10.1093/ annonc/mdi185.

- Kalofonos HP, Aravantinos G, Kosmidis P, et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol. 2005;16:869–77. https://doi.org/10.1093/annonc/mdi193.

- Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo OncologicoDell'Italia Meridionale. J Clin Oncol. 2005;23:4866–75. https://doi.org/10.1200/JCO.2005.07.113.

Downloads

Published

2022-11-09

Issue

Vol. 55 No. 3 (2022)

Section

Review

License

Copyright (c) 2022 Thais Arabe Prado, Giovanna Volpe Del Bel, Milena Bongiorno Levignali, Uanderson Resende

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 

 

How to Cite

1.
Prado T Árabe do, Del Bel GV, Levignali MB, Resende U. Oxaliplatin versus Irinotecan in advanced colorectal cancer. Medicina (Ribeirão Preto) [Internet]. 2022 Nov. 9 [cited 2024 May 15];55(3):e-189669. Available from: https://www.revistas.usp.br/rmrp/article/view/189669